Get the Stockscreener App
0.339
0.59%
0.0019
Senseonics Holdings Inc stock is traded at $0.339, with a volume of 2.54M.
It is up +0.59% in the last 24 hours and down -1.14% over the past month.
Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days. The company has a research and development license agreement with TypeZero Technologies, Inc. and Roche Diabetes Care, Inc. to develop a closed loop diabetes management system that allow users to automatically maintain tight glucose control while avoiding hypoglycemia. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
See More
Previous Close:
$0.3371
Open:
$0.3372
24h Volume:
2.54M
Relative Volume:
0.64
Market Cap:
$195.95M
Revenue:
$22.39M
Net Income/Loss:
$-60.39M
P/E Ratio:
-1.8647
EPS:
-0.1818
Net Cash Flow:
$-70.51M
1W Performance:
-2.98%
1M Performance:
-1.14%
6M Performance:
-32.84%
1Y Performance:
-36.75%
1-Day Range:
$0.33
$0.342
1-Week Range:
$0.33
$0.369
52-Week Range:
$0.32
$0.75
Senseonics Holdings Inc Stock (SENS) Company Profile
Name
Senseonics Holdings Inc
Sector
Industry
Phone
301-515-7260
Address
20451 Seneca Meadows Parkway, Germantown, MD
Senseonics Holdings Inc Stock (SENS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-05-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jan-21-21 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-20-21 | Downgrade | Craig Hallum | Hold → Sell |
| Aug-11-20 | Upgrade | BTIG Research | Neutral → Buy |
| Aug-11-20 | Upgrade | Craig Hallum | Sell → Hold |
| Mar-13-20 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-13-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-13-19 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-23-19 | Initiated | Stifel | Buy |
| Jul-05-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-29-19 | Initiated | Piper Jaffray | Neutral |
| Aug-24-18 | Initiated | Dougherty & Company | Buy |
View All
Senseonics Holdings Inc Stock (SENS) Latest News
What Did We Find About Insider Trading At Senseonics Holdings Inc (AMEX: SENS)? - Stocks Register
Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com - MarketBeat
Senseonics stock dips on $16M securities offering - MSN
Senseonics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - Quantisnow
Senseonics Holdings Expands Equity and Financial Strategy - TipRanks
Senseonics announces $16 million stock and warrant sale By Investing.com - Investing.com Canada
Senseonics announces $16 million stock and warrant sale - Investing.com
Senseonics Holdings, Inc. Announces $16 Million Registered Direct Offering - GlobeNewswire
SENSSenseonics Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Senseonics Holdings, Inc. Schedules Third Quarter 2024 - GlobeNewswire
Senseonics Holdings, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for November 7, 2024 at 4:30 P.M. Eastern Time - Quantisnow
Senseonics Holdings (STU:6L6) 3-Year Revenue Growth Rate : 21.00% (As of Jun. 2024) - GuruFocus.com
Senseonics Holdings (STU:6L6) Revenue per Share : €0.04 (TTM As of Jun. 2024) - GuruFocus.com
Senseonics Holdings (STU:6L6) Cost of Goods Sold : €19.56 Mil (TTM As of Jun. 2024) - GuruFocus.com
Senseonics Holdings (STU:6L6) Forward Dividend Yield % : 0.00% (As of Oct. 23, 2024) - GuruFocus.com
Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com - MarketBeat
Senseonics to Host Virtual KOL Event on Eversense 365: FDA - GlobeNewswire
Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System - StockTitan
The time has not yet come to remove your chips from the table: Senseonics Holdings Inc (SENS) - SETE News
Investing in Senseonics Holdings Inc (SENS) Is Getting More Attractive - Knox Daily
StockNews.com Begins Coverage on Senseonics (NYSE:SENS) - MarketBeat
Analyzing the Impact of Earnings Reports on Senseonics Holdings Inc Inc. (SENS) Price Performance - The InvestChronicle
Financial Snapshot: Analyzing Senseonics Holdings Inc (SENS)’s Key Ratio Metrics - The Dwinnex
Senseonics Holdings Inc (SENS) requires closer examination - US Post News
Eversense 365 CGM system launches for year-long diabetes monitoring By Investing.com - Investing.com Australia
Eversense 365 CGM system launches for year-long diabetes monitoring - Investing.com India
Mercy Places First Commercial Eversense 365: The World’s First and Only 365-Day Continuous Glucose Monitor - GlobeNewswire
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor - PR Newswire
SENS’s latest rating updates from top analysts. - Knox Daily
Stock Performance Spotlight: Senseonics Holdings Inc (SENS) Ends the Day at 0.34, Up by 3.00 - The Dwinnex
StockNews.com Initiates Coverage on Senseonics (NYSE:SENS) - MarketBeat
Eversense 365 Launches in the US: One Year. One CGM. – Company Announcement - Financial Times
Can you now get a good deal on Senseonics Holdings Inc’s shares? - US Post News
Senseonics Stock Down Despite New FDA Approval for Eversense 365 - MSN
State of New Jersey Common Pension Fund D Sells 27,371 Shares of Sensata Technologies Holding plc (NYSE:ST) - Defense World
Sensata Technologies (NYSE:ST) Releases Q3 2024 Earnings Guidance - Defense World
SenesTech stock hits 52-week low at $2.4 amid sharp decline - Investing.com
Senseonics Eversense 365 glucose monitor cleared in the U.S. - MSN
Eversense 365, a 1-Year CGM, Cleared by the FDA - diaTribe Foundation
FDA Clears First 1-Year CGM for Diabetes - Drug Topics
Investing in Senseonics Holdings Inc (SENS): What You Must Know - Knox Daily
FDA Clearance Announcement Sends Small Cap Soaring - MSN
Senseonics and Ascensia announce FDA approval for one-year CGM system - Medical Device Network
Market Highlights: Senseonics Holdings Inc (SENS) Ends on a High Note at 0.44 - The Dwinnex
Stifel maintains Buy rating on Senseonics, cites FDA approval By Investing.com - Investing.com Canada
FDA approves Eversense 365 as year-long diabetes monitor - Investing.com
FDA Clears Eversense® 365: The World’s First One-Year CGM System - HIT Consultant
FDA clears Senseonic’s Eversense one-year implantable CGM - BioWorld Online
Senseonics Holdings Inc Stock (SENS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):